Clinical Trial Update: Abatacept to Silence Anti-citrullinated Protein Antibody-expressing B Cells in Rheumatoid Arthritis (ASCARA) [Phase 4]

View source ↗

Summary

Phase 4 trial assessing abatacept’s ability to silence anti-citrullinated protein antibody-expressing B cells in rheumatoid arthritis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Abatacept (abatacept)

Snippet

Sponsor: Leiden University Medical Center | Conditions: Rheumatoid Arthritis, Rheumatic Diseases | Phase 4 | Status: COMPLETED